Peptomyc SL
OMO-103 in Phase 1b clinical trial
BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.
Peptomyc logo
MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.
Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".
This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Muñoz at the Hospital Gregorio Marañon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.
About Peptomyc
Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.
Contact Information
Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869
SOURCE: Peptomyc SL
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/770698/Peptomyc-Announces-the-Approval-of-Its-Phase-1b-Trial-Testing-OMO-103-in-Combination-With-Standard-of-Care-in-PDAC-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SafeHeal(R) Receives European Marketing Approval Under MDR for Colovac(R) Anastomosis Protection Technology14.8.2025 22:45:00 CEST | Press release
Marketing approval allows imminent commercialization of the Colovac device in key EU markets PARIS, FRANCE AND TAMPA, FL / ACCESS Newswire / August 14, 2025 / SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced that it has been granted European Union marketing approval for its Colovac device under the new Medical Device Regulation (EU MDR 2017/745, Medical Devices, Annex IX Chapter I). This significant milestone confirms the company's compliance with the EU's rigorous safety and performance standards, enabling commercial distribution of Colovac across the European Union. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.1,2 "This is a pivotal achievement for our company and a testament to the dedication of our regulatory, clinical, and engineering teams," said Chris Richardson, President and Chief Executive Officer of SafeHeal. "We are now ready to bring the clinical and economic
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements14.8.2025 17:00:00 CEST | Press release
Comprehensive updates improve asset protection, governance, and dispute resolution mechanisms RAS AL KHAIMAH CITY, UAE / ACCESS Newswire / August 14, 2025 / Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection. RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity. The 2025 amendments introduce stronger legal safeguards and improved governance me
8849 TANK 4 - the Rugged Phone With 720P Projector & AMOLED Screen - Now on Aliexpress!14.8.2025 15:00:00 CEST | Press release
8849 is excited to introduce the latest addition to its lineup - TANK 4. Packed with cutting-edge features, the phone is set to redefine what a rugged phone can do. The 8849 Unihertz TANK 4 launches on Aliexpress this August 18. Don't miss the opportunity to own the ultimate rugged smartphone. SHENZHEN, CN / ACCESS Newswire / August 14, 2025 / In the world of mobile devices, 8849 has always been a symbol of quality and innovation. Now, 8849 is excited to introduce the latest addition to its lineup - TANK 4. Packed with cutting-edge features, the phone is set to redefine what a rugged phone can do.8849 phone projector rugged phone Never miss movie night, even in the wild! The TANK 4 comes with a 720P DLP projector that boasts 100 lumens and auto-focus, delivering crisp visuals anywhere. Whether the user is camping or giving a presentation, this phone transforms any wall into a big screen. Experience buttery-smooth scrolling and vibrant colors on the 6.78" AMOLED display with a 120Hz ref
Picktan Capital's Future Proof Fund Raises $500 Million in Breakout Launch - Fully Subscribed Amid Surging Demand14.8.2025 15:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / August 14, 2025 / Picktan Capital, a London-headquartered wealth management firm managing over $7 billion in client assets globally, a leader in forward-focused investment strategies, has officially launched its Future Proof Fund, raising $500 million in its initial offering, which is now fully subscribed following an overwhelmingly positive investor response. The Future Proof Fund targets companies driving the next wave of global innovation, with strategic focus areas including: Artificial Intelligence Robotics & Automation Autonomous Systems Fintech & Digital Infrastructure "We built the Future Proof Fund for investors who want more than growth, they want to own the future," said Richard Hart, Head of Private Equity at Picktan Capital. "The fact that we raised $500 million and reached full subscription so quickly is a testament to how strong the demand is for exposure to the sectors that will define the next decade." Due to the strength of demand, Pickt
Loar Holdings Inc. Reports Q2 2025 Record Results and Upward Revision to 2025 Outlook and Announces the Acquisition of Beadlight Ltd.13.8.2025 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / August 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the second quarter of 2025, upward revision to 2025 guidance, and announces the acquisition of Beadlight Ltd. ("Beadlight"). "Strong execution of our value drivers, combined with the rich proprietary content of our diversified portfolio of capabilities aligned perfectly to achieve these record results in the second quarter," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "Each of our end markets experienced record sales, with Commercial OEM being up 18%, Commercial Aftermarket up 29%, and Defense growing 51% as compared to the second quarter of 2024. In addition, I am excited to welcome the team at Beadlight Ltd. to Loar. Beadlight is our 18th completed acquisition since inception in 2012." Second Quarter 2025 Net sales of $123.1 million, up 26.9% compared to the prior year's quarter. Net i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom